Myovant Sciences Share Holder Equity 2017-2022 | MYOV

Myovant Sciences share holder equity from 2017 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Myovant Sciences Annual Share Holder Equity
(Millions of US $)
2022 $-473
2021 $-354
2020 $-108
2019 $4
2018 $38
2017 $167
2016 $-0
Myovant Sciences Quarterly Share Holder Equity
(Millions of US $)
2022-06-30 $-484
2022-03-31 $-473
2021-12-31 $-432
2021-09-30 $-383
2021-06-30 $-400
2021-03-31 $-354
2020-12-31 $-271
2020-09-30 $-200
2020-06-30 $-135
2020-03-31 $-108
2019-12-31 $-49
2019-09-30 $17
2019-06-30 $80
2019-03-31 $4
2018-12-31 $47
2018-09-30 $74
2018-06-30 $60
2018-03-31 $38
2017-12-31 $82
2017-09-30 $119
2017-06-30 $146
2017-03-31 $167
2016-12-31 $186
2016-09-30 $-38
2016-06-30 $-9
2016-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.391B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $152.564B 9.26
GSK (GSK) United Kingdom $61.844B 7.43
Bio-Rad Laboratories (BIO.B) United States $13.545B 29.93
QIAGEN (QGEN) Netherlands $9.898B 16.57
Ginkgo Bioworks Holdings (DNA) United States $5.908B 0.00
Arcus Biosciences (RCUS) United States $2.007B 39.18
Emergent Biosolutions (EBS) United States $1.039B 6.02
Biohaven Pharmaceutical Holding (BHVN) United States $0.878B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.392B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Enzo Biochem (ENZ) United States $0.113B 0.00
Gelesis Holdings (GLS) United States $0.087B 0.00
SQZ Biotechnologies (SQZ) United States $0.075B 0.00
Ambrx Biopharma (AMAM) United States $0.045B 0.00